Skip to main content

Outcomes

RheumNow Podcast square

Telemedicine Upside Interview with Dr. Alvin Wells

Dec 03, 2021

In spite of the transformative growth of telemedicine during the COVID-19 pandemic, rheumatologists use of telemedicine is waning, much like the use of masks. Dr. Jack Cush interviews telemedicine guru, Dr. Alvin Wells, on the current state of telemedicine and what the future holds for

Read Article
dementia,brain

Rheumatoid Arthritis, Dementia and Cognitive Dysfunction

Dec 02, 2021

Rheumatoid arthritis (RA) has been linked to a higher risk of dementia and cognitive dysfunction, but interestingly this association has diminished in the last few decades with aggressive DMARD and targeted therapies..



This makes sense when you see that dementia in RA is associated

Read Article
lung%2Cbright.jpg

Cytokine Inhibitor Lung Disease in Still's Linked to HLA-DRB1 Alleles

Dec 01, 2021

Pulmonary complications in the setting of Still's disease (juvenile and adult) has seldom but consistently been reported, including reports of pneumonitis, pulmonary hypertension and a severe or fatal lung disease, often associated with hypersensitivity to anticytokine therapy. A multicenter

Read Article
Sle.vote_.criteria.png

DORIS - Defining Remission in Lupus

Nov 29, 2021

Proponents of treat to target in systemic lupus erythematosus (SLE) have all agreed that "remission" should be the goal, but defining remission may be tricky in SLE.  A SLE Definitions Of Remission (DORIS)Task Force was convened in 2015 and first published their work in 2016. Now the 2021

Read Article
Dr. Jack Cush interviews Professor Edward Keystone, MD (University of Toronto) on the origins and science behind the 60/40/20 benchmark and outcomes in rheumatoid arthritis.https://t.co/Ve6zOQPxZJ https://t.co/8RuL2CCsOQ
Dr. John Cush @RheumNow( View Tweet )
Nov 29, 2021
ICYMI: Data on Existing SLE Medications, Patient Centered Outcomes, and Exercise: Dr. Michelle Petri discusses data on existing SLE medications, patient-centered outcomes and the importance of exercise, presented Monday at the #ACR21 annual meeting.https://t.co/SQOLQRmQtp https://t.co/ZA1uISdGyk
Dr. John Cush @RheumNow( View Tweet )
Nov 28, 2021
keystone

RheumNow Podcast - 60/40/20 Interview with Dr. Ed Keystone

Nov 26, 2021

Dr. Jack Cush interviews Professor Edward Keystone, MD (University of Toronto) on the origins and science behind the 60/40/20 benchmark and outcomes in rheumatoid arthritis.


Read Article
rachel.tate

Safety of Psoriatic Biologics in Pregnancy

Nov 24, 2021

Little is known about the safety of newer biologic use during pregnancy, especially in patients who either conceive while on a biologic or must remain on a biologic during pregnancy (often the case with IBD and inflammatory arthritis). A report from ACR 2021 (Abstract 1713) examined the risk

Read Article
jon.kay

Does Control of Inflammation Lower Cancer Risk?

Nov 23, 2021

Dr. Jonathan Kay's provocative video addresses whether the increased cancer risk associated with tofacitinib (Tofa) seen in the Pfizer Oral Surveillance (1133) study represents a real increased risk, an increased risk relative to a decreased risk with TNF inhibitors (TNFi) or an actual decreased

Read Article
phone.jpg

Improving Rheumatology Practice

Nov 22, 2021

How to best book patient appointments in rheumatology clinic? Should these be scheduled every 3 or 4 months regardless of patient status? Should they be scheduled by patient need or disease activity? 

Read Article
HAQ.RAPID

RAPID3 in Assessing Psoriatic Arthritis

Nov 18, 2021

My research shows that up to 50% of rheumatologists measure something in the course of their daily assessments, and RAPID3 is most popular, being employed by 31% of rheumatologists.

Read Article
Conway still

GLORIA Study - Is Prednisone Harmful in Elder RA?

Nov 17, 2021

The GLORIA study (ABST# 1678) was a pragmatic, blinded placebo-controlled randomized trial from Dr. Martin Boers and colleagues where they assessed whether prednisolone (vs. placebo) use would alter clinical outcomes over 2 years.



A total of 451 elder patients with established RA

Read Article
PSA2L.jpg

An Old Friend – Methotrexate in Psoriatic Arthritis

Nov 16, 2021

Methotrexate (MTX) remains one of our most used and reliable tools against a variety of rheumatic diseases, including PsA. When the time comes, as it often does, to escalate from a MTX-monotherapy approach, we have several options. In clinic, initiation of these other medications has often been

Read Article
covid coronavirus virus

More severe COVID-19 outcomes in African American, Hispanic individuals with SLE

A study from ACR21 convergence discussing data from the Global Rheumatology Alliance (GRA) describes the association between race/ethnicity on COVID-19 outcomes specifically in lupus patients.

Read Article
RheumNow Podcast square

RheumNow Podcast - ACR 2021 Rehash (the good stuff..)

Nov 12, 2021

The ACR 2021 meeting has concluded. Dr. Jack Cush recounts a few more great abstracts from this past week’s virtual meeting.

Read Article
DPGN, lupus, nephritis, GN, glomerulonephritis, biopsy, kidney

Racial/ethnic disparity in U.S. lupus nephritis mortality

At #ACR21, the plenary session included an analysis of deaths from SLE throughout the US comparing 1999 to 2019 (Abstract #0454).

Read Article
unhappy%20patient.jpg

Psoriatic Arthritis: "What Matters" to Patients, Physicians

A study presented today by Mease et al. addresses the vital gap between what patients and physicians consider disabling because of PsA, and emphasizes “what matters” in a daily clinical encounter while dealing with PsA.

Read Article
audience learn

Day 4 Report from ACR21

Nov 10, 2021

My favorite three presentations from day 4 (Tuesday) at ACR 2021 included the following.

Read Article
Malar,rash,SLE, Lupus

Predictors of Remission and Low Disease Activity in SLE

Nov 10, 2021

A treat-to-target strategy has been shown to improve clinical outcomes in patients with rheumatic diseases like rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis including systemic lupus erythematosus.  The goal of treatment in SLE is aimed at remission or low disease activity

Read Article
EULAR19.abstract.jpg (keep)

ACR21 – Day 3 Report

Nov 09, 2021

Hitting the home stretch, day 3 presentations were big! Here are a few of my favorites: secukinumab efficacy in juvenile PsA; VEXAS - predicting poor outcomes; and the FDA Safety Update session.

Read Article
Thank you @AhmadSherbini for discussing his #ACR21 research on @RheumNow on Abs#1444 - Can we predict which patients are most likely to have nausea or alopecia intolerance to MTX?https://t.co/I5WmCECq7v
Nov 09, 2021
Racial differences in PsA patients in large US real world database 95% Whites (W) and 5% were AA NSAIDs: 80% W and 78% AAs TNFI: 51% W and 41% of AAs DMARDs: 72% of W and 98% of AAs HTN/DM/Obesity/Gout 🔼 AA Cancer/osteoporosis /anxiety 🔼 whites Abst#1780 #ACR21 @Rheumnow https://t.co/7ee4bVU7ZA
swethaann23 @swethaann23( View Tweet )
Nov 09, 2021
Racial disparities & Co-morbidities in PsA findings. Amongst important others, increased biologic use in Caucasians w/ PsA vs DMARDs in black PsA pts. View Abs 1780 for other relevant findings. #ACR21 #RheumNow #ACRbest @RheumNow https://t.co/0uKsa8i0bG https://t.co/R9YkxYqXws
Dr. Rachel Tate @uptoTate( View Tweet )
Nov 09, 2021
rare

Risks associated with mortality in VEXAS

Vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic syndrome (VEXAS) took the centre stage when it was first introduced at ACR20 last year. It got everyone’s thinking that they might have encountered one or two patients in their rheumatology lifetime who might have this condition. One

Read Article
Minority (African American and Hispanic) #SLE patients have worse #COVID19 outcomes – double whammy! Data from the @rheum_covid #ACR21 @rheumnow #abst1933
Nov 09, 2021
×